GCM
IPSC icon

Gladius Capital Management’s Century Therapeutics IPSC Stock Holding History

Gladius Capital Management’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-9,810
Closed -$19.6K – 368
2023
Q3 		$19.6K Buy
9,810
+3,564
+57% +$9.48K ﹤0.01% 341
2023
Q2 		$19.7K Sell
6,246
-1,484
-19% -$4.78K ﹤0.01% 304
2023
Q1 		$26.8K Buy
+7,730
New +$33.9K ﹤0.01% 301

Other funds holding IPSC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Gladius Capital Management's IPSC Position: Q4 2023 in Review

Gladius Capital Management sold out of Century Therapeutics (IPSC) in Q4 2023, closing a stake of 9,810 shares — an estimated $19.6K sold.

Gladius Capital Management first reported a position in IPSC in Q1 2023 and held it in 3 quarters. The position peaked at $26.8K in Q1 2023. 63 funds tracked by Wall St. Rank hold IPSC as of Q4 2023.

  • Gladius Capital Management reported no remaining Century Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Gladius Capital Management sold 9,810 Century Therapeutics shares in Q4 2023, an estimated $19.6K.
  • Gladius Capital Management first reported a position in Century Therapeutics in Q1 2023 and held it in 3 quarters.
  • Gladius Capital Management's Century Therapeutics position peaked at $26.8K in Q1 2023.
  • 63 funds tracked by Wall St. Rank held Century Therapeutics as of Q4 2023.

Based on Gladius Capital Management's 13F filing for Q4 2023, filed 7 Feb 2024.